Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

Guerbet

Status and phase: Completed; Phase 2

Conditions: Pediatric Disorder; Central Nervous System Diseases; Body Indication

Treatments: Drug: Gadopiclenol

Study type: Interventional

Funder types: Industry

Identifiers

NCT05590884

GDX-44-015

Details and patient eligibility

About

This Phase II open-label, uncontrolled, multicenter trial is designed to investigate the pharmacokinetic (PK) profile of gadopiclenol in plasma, in pediatric patients aged up to 23 months inclusive (term neonates or preterm infants after the neonatal period), using a population PK approach.

Primary objective is to evaluate the PK profile of gadopiclenol in plasma following single intravenous injection of 0.05 mmol/kg body weight (BW) in pediatric population aged up to 23 months (inclusive) scheduled for a contrast-enhanced MRI examination of any body region including central nervous system (CNS).

Full description

Three age groups are defined:

• Group 1: patients aged 3 to 23 months (inclusive)
• Group 2: patients aged 28 days to less than 3 months;
• Group 3: patients aged from birth to 27 days (term newborns).

At study set-up, the inclusions started with the oldest patients in group 1 and using an age-down staggered approach.

The decision to start the inclusions in group 2 was taken by the Trial Safety Review Board based on safety assessment over one-day period after injection of the first 13 patients in group 1.

According to the protocol version 4 (amendments 2 & 3), the age-down staggered approach was discontinued to allow the inclusions in Group 3 (patients aged from birth to 27 days), simultaneously to inclusions in group 1 and group 2.

A total of 3 blood samples per patient were taken post-injection for PK analysis.

Enrollment: 36 patients

Sex: All

Ages: Under 23 months old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Main Inclusion Criteria:

1. Female or male pediatric patient aged from birth to 23 months of age inclusive (term neonates for all age groups or preterm infants after the neonatal period for groups 1 or 2). The neonatal period for preterm newborns is defined as the day of birth through the expected date of delivery plus 27 days. Term is defined as ≥37 completed weeks of amenorrhea,
2. Patient with known or highly suspected abnormalities/ lesion(s), scheduled to undergo contrast-enhanced MRI of any body region including CNS [...]

Main Exclusion Criteria:

1. Patient planned for treatment or procedure (e.g. surgery) that would prevent from obtaining the required blood samples or performing other trial procedures between the screening visit and up to one day after gadopiclenol administration,
2. Patient undergoing treatment or procedure (e.g., diuretics, clinically significant blood loss or blood transfusion) preceding or subsequent to gadopiclenol administration that would alter gadopiclenol pharmacokinetic parameters,
3. Patient with acute or chronic renal insufficiency defined as estimated Glomerular Filtration Rate (eGFR) out of age-adjusted normal value calculated based on bedside Schwartz equation, [...]

9. Patient undergoing a change in chemotherapy (product or dosage) within one day prior to or one day after gadopiclenol administration, 10. Patient who received or will receive any other contrast agent for CT and/or MRI within one week prior to or one week after gadopiclenol administration, 11. Patient with contraindication for MRI such as iron metal implants (e.g., aneurysm clips, pacemaker), 12. Patient with history of anaphylactoid or anaphylactic reaction to any allergen including drugs and contrast agents [...]

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

36 participants in 3 patient groups

Age Group 1: patients aged 3 to 23 months

Experimental group

Description:

One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.

Treatment:

Drug: Gadopiclenol

Age Group 2: patients aged 28 days to less than 3 months

Experimental group

Description:

One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.

Treatment:

Drug: Gadopiclenol

Age Group 3: patients aged from birth to 27 days (term newborns)

Experimental group

Description:

One Investigational Medicinal Product (IMP) dose of 0.05 mmol/kg will be injected in all patients.

Treatment:

Drug: Gadopiclenol